178 related articles for article (PubMed ID: 29934691)
1. A new iron(III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii.
Portes JA; Azeredo NFB; Siqueira PGT; de Souza TG; Fernandes C; Horn A; Candela DRS; de Souza W; DaMatta RA; Seabra SH
Parasitol Res; 2018 Sep; 117(9):2795-2805. PubMed ID: 29934691
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin and Simvastatin Pretreatment in Combination with Pyrimethamine and Sulfadiazine Reduces Infection Process of Toxoplasma gondii Tachyzoites (RH Strain) in HeLa Cells.
Sanfelice RADS; da Silva SS; Bosqui LR; Machado LF; Miranda-Sapla MM; Panagio LA; Navarro IT; Conchon-Costa I; Pavanelli WR; Almeida RS; Costa IN
Acta Parasitol; 2019 Sep; 64(3):612-616. PubMed ID: 31286354
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.
Portes JA; Souza TG; dos Santos TA; da Silva LL; Ribeiro TP; Pereira MD; Horn A; Fernandes C; DaMatta RA; de Souza W; Seabra SH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7374-86. PubMed ID: 26392498
[TBL] [Abstract][Full Text] [Related]
5. Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.
Silva LA; Reis-Cunha JL; Bartholomeu DC; Vítor RW
PLoS One; 2017; 12(1):e0170689. PubMed ID: 28118394
[TBL] [Abstract][Full Text] [Related]
6. Sulfadiazine Sodium Ameliorates the Metabolomic Perturbation in Mice Infected with Toxoplasma gondii.
Zhou CX; Gan Y; Elsheikha HM; Chen XQ; Cong H; Liu Q; Zhu XQ
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383652
[TBL] [Abstract][Full Text] [Related]
7. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent.
Prieto MJ; Bacigalupe D; Pardini O; Amalvy JI; Venturini C; Morilla MJ; Romero EL
Int J Pharm; 2006 Dec; 326(1-2):160-8. PubMed ID: 16920292
[TBL] [Abstract][Full Text] [Related]
8. Further evidence that naphthoquinone inhibits Toxoplasma gondii growth in vitro.
da Silva LL; Portes Jde A; de Araújo MH; Silva JL; Rennó MN; Netto CD; da Silva AJ; Costa PR; De Souza W; Seabra SH; DaMatta RA
Parasitol Int; 2015 Dec; 64(6):622-31. PubMed ID: 26335616
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative synergism of azasterols and antifolates against Toxoplasma gondii.
Dantas-Leite L; Urbina JA; de Souza W; Vommaro RC
Int J Antimicrob Agents; 2005 Feb; 25(2):130-5. PubMed ID: 15664482
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Selective Halogen-Substituted Imidazole-Thiosemicarbazides for Inhibition of
Paneth A; Węglińska L; Bekier A; Stefaniszyn E; Wujec M; Trotsko N; Hawrył A; Hawrył M; Dzitko K
Molecules; 2019 Apr; 24(8):. PubMed ID: 31022878
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and In Vitro Anti-
Trotsko N; Bekier A; Paneth A; Wujec M; Dzitko K
Molecules; 2019 Aug; 24(17):. PubMed ID: 31438527
[TBL] [Abstract][Full Text] [Related]
12. Anti-parasitic activity of a chimeric peptide Cecropin A (2-8)-Melittin (6-9) (CM11) against tachyzoites of Toxoplasma gondii and the BALB/c mouse model of acute toxoplasmosis.
Abbasali Z; Pirestani M; Dalimi A; Badri M; Fasihi-Ramandi M
Mol Biochem Parasitol; 2023 Sep; 255():111578. PubMed ID: 37348706
[TBL] [Abstract][Full Text] [Related]
13. A new type of pterocarpanquinone that affects Toxoplasma gondii tachyzoites in vitro.
Portes Jde A; Netto CD; da Silva AJ; Costa PR; DaMatta RA; dos Santos TA; De Souza W; Seabra SH
Vet Parasitol; 2012 May; 186(3-4):261-9. PubMed ID: 22177332
[TBL] [Abstract][Full Text] [Related]
14. Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.
de Lima LP; Seabra SH; Carneiro H; Barbosa HS
Antimicrob Agents Chemother; 2015 Sep; 59(9):5239-49. PubMed ID: 26077255
[TBL] [Abstract][Full Text] [Related]
15. Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.
Dzitko K; Grzybowski MM; Pawełczyk J; Dziadek B; Gatkowska J; Stączek P; Długońska H
Parasit Vectors; 2015 Aug; 8():422. PubMed ID: 26272689
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.
Aspinall TV; Joynson DH; Guy E; Hyde JE; Sims PF
J Infect Dis; 2002 Jun; 185(11):1637-43. PubMed ID: 12023770
[TBL] [Abstract][Full Text] [Related]
17. Lectins from
; Ramos EL; Santana SS; Silva MV; Santiago FM; Mineo TW; Mineo JR
Front Cell Infect Microbiol; 2016; 6():164. PubMed ID: 27933277
[TBL] [Abstract][Full Text] [Related]
18. Dynamin inhibitor impairs Toxoplasma gondii invasion.
Caldas LA; Attias M; de Souza W
FEMS Microbiol Lett; 2009 Nov; 301(1):103-8. PubMed ID: 19817867
[TBL] [Abstract][Full Text] [Related]
19. Anti-Toxoplasma gondii effect of tylosin in vitro and in vivo.
Han RX; Jiang PC; Han B; Zhou HY; Wang YL; Guan JY; Liu ZR; He SY; Zhou CX
Parasit Vectors; 2024 Feb; 17(1):59. PubMed ID: 38341599
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Köksal ZŞ; Yanik K; Bilgin K; Yılmaz EM; Hokelek M
Jpn J Infect Dis; 2016; 69(2):113-7. PubMed ID: 26166498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
